The Advisory Committee's positive recommendation acknowledges the strength of our data and the importance of a protein-based COVID-19 vaccine developed using an innovative approach to traditional vaccine technology, we have heard in today's VRBPAC meeting the significant support for our vaccine from physicians, healthcare organizations, and consumers who are eagerly anticipating a protein-based vaccine option.

Stanley Erck

In the US, I think it will be the booster for everyone, particularly if we get it out late in the third quarter, it's going to be time to start boosting -- whether it's six months or at a year point.

We are very encouraged by the data showing that NVX-CoV2373 not only provided complete protection against the most severe forms of disease but also dramatically reduced mild and moderate disease across both trials, importantly, both studies confirmed efficacy against the variant strains.

I think we have a high level of confidence that that our vaccine will set off the appropriate immune response to generate lots of antibodies.